In this short video, InMed’s CEO, Eric A. Adams, provides a summary of the preclinical studies of INM-901, the company’s drug candidate in the potential treatment of Alzheimer’s disease.
INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.
